GenomeKey employs genomic sequencing technology to analyze genetic data for early disease detection and the formulation of personalized treatment plans. By providing precise genomic insights, the company enhances patient outcomes through targeted healthcare interventions.
Funding
$3M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Current gold standard tests for bacterial infections take too long and have a high false-negative rate, delaying targeted treatment and contributing to high mortality rates from sepsis and antimicrobial resistance (AMR). Millions are affected by sepsis every year, and someone dies from sepsis every few seconds.
Solution
GenomeKey is developing a next-generation in vitro diagnostic (IVD) device that rapidly detects bacteria, identifies the specific pathogen, and provides a comprehensive antimicrobial resistance (AMR) profile directly from a patient's blood sample. The GenomeKey\[Dx] device delivers results in hours, enabling clinicians to prescribe the right antibiotic early in the course of infection. This technology aims to transform sepsis treatment by providing fast, reliable, and accessible diagnostics to improve patient outcomes and combat antimicrobial resistance.
Target Audience
The primary target audience includes clinicians, hospitals, and healthcare providers involved in the diagnosis and treatment of sepsis and other bacterial infections.
Features
- Rapid bacterial detection and identification directly from blood samples
- Comprehensive AMR profiling to guide targeted antibiotic therapy
- Results available in hours, significantly faster than traditional methods
- High accuracy in predicting antibiotic resistance
- Low-cost and easily integrated device for broad accessibility
- Covers 100% of pathogens in a single test